210 related articles for article (PubMed ID: 34131801)
21. Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive.
Ahrendsen JT; Ta R; Li J; Weinberg OK; Ferry JA; Hasserjian RP; Meredith DM; Varma H; Sadigh S; Michaels PD
Am J Clin Pathol; 2022 Aug; 158(2):300-310. PubMed ID: 35460414
[TBL] [Abstract][Full Text] [Related]
22. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
[TBL] [Abstract][Full Text] [Related]
23. Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase.
Monaco S; Tsao L; Murty VV; Nandula SV; Donovan V; Oesterheld J; Bhagat G; Alobeid B
Am J Hematol; 2007 Jan; 82(1):59-64. PubMed ID: 16955462
[TBL] [Abstract][Full Text] [Related]
24. Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.
Choi JW; Lee Y; Kim H; Cho HY; Min SK; Kim YS
Am J Surg Pathol; 2022 Feb; 46(2):241-248. PubMed ID: 34619707
[TBL] [Abstract][Full Text] [Related]
25. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
26. C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC.
Moritake H; Shimonodan H; Marutsuka K; Kamimura S; Kojima H; Nunoi H
Am J Hematol; 2011 Jan; 86(1):75-8. PubMed ID: 21080342
[TBL] [Abstract][Full Text] [Related]
27. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892
[No Abstract] [Full Text] [Related]
29. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
30. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases.
Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ
Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163
[TBL] [Abstract][Full Text] [Related]
32. Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Rigaud C; Abbas R; Grand D; Minard-Colin V; Aladjidi N; Buchbinder N; Garnier N; Plat G; Couec ML; Duplan M; Lambilliotte A; Schmitt C; Leblanc T; Lamant L; Brugières L
Pediatr Blood Cancer; 2021 Jun; 68(6):e28982. PubMed ID: 33687135
[TBL] [Abstract][Full Text] [Related]
33.
Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
Gascoyne RD; Aoun P; Wu D; Chhanabhai M; Skinnider BF; Greiner TC; Morris SW; Connors JM; Vose JM; Viswanatha DS; Coldman A; Weisenburger DD
Blood; 1999 Jun; 93(11):3913-21. PubMed ID: 10339500
[TBL] [Abstract][Full Text] [Related]
35. Primary central nervous system ALK-positive anaplastic large cell lymphoma with CD56 abnormally expression in a Chinese child: Challenge in diagnostic practice.
Liu Q; Chen X; Li G; Ye Y; Liu W; Zhao S; Zhang W
Int J Immunopathol Pharmacol; 2020; 34():2058738420941756. PubMed ID: 32664812
[TBL] [Abstract][Full Text] [Related]
36. Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.
Gerbe A; Alame M; Dereure O; Gonzalez S; Durand L; Tempier A; De Oliveira L; Tourneret A; Costes-Martineau V; Cacheux V; Szablewski V
Virchows Arch; 2019 Aug; 475(2):163-174. PubMed ID: 30953147
[TBL] [Abstract][Full Text] [Related]
37. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.
Parkhi M; Bal A; Das A; Kashyap D; Bhardwaj S; Prakash G; Malhotra P
Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):648-656. PubMed ID: 33901030
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
40. Characteristics And Outcomes Of Anaplastic Large Cell Lymphoma Patients-A Single Centre Experience.
Athar S; Siddiqui N; Hameed A
J Ayub Med Coll Abbottabad; 2017; 29(1):37-41. PubMed ID: 28712170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
